Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1983 Apr;42(2):155–157. doi: 10.1136/ard.42.2.155

Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone.

R A Hazelton, A B McCruden, R D Sturrock, W H Stimson
PMCID: PMC1001090  PMID: 6342550

Abstract

Ten patients (8 female, 2 male) with systemic lupus erythematosus (SLE) were entered into an open trial with the anabolic steroid 19-nortestosterone (19-nor). Their clinical condition did not improve, nor were significant changes observed in the majority of laboratory data. However, overall the platelet count rose, and in patients with abnormal levels of T lymphocytes bearing receptors for IgG Fc treatment returned the values to normal. Despite this latter result, suppressor cell activity remained slightly below the normal range throughout the study period.

Full text

PDF
155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapel T. A., Burns R. E. Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol. 1971 Jun 1;110(3):366–369. doi: 10.1016/0002-9378(71)90730-7. [DOI] [PubMed] [Google Scholar]
  2. Gupta S., Good R. A. Human T cell subpopulations as defined by Fc receptors. Thymus. 1979 Nov;1(3):135–149. [PubMed] [Google Scholar]
  3. Lydyard P. M., Fanger M. W. Receptors for IgM on human lymphocytes. II. Mitogen-induced modulation of receptor expression. Clin Exp Immunol. 1979 Sep;37(3):486–494. [PMC free article] [PubMed] [Google Scholar]
  4. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  5. Miller K. B., Schwartz R. S. Familial abnormalities of suppressor-cell function in systemic lupus erythematosus. N Engl J Med. 1979 Oct 11;301(15):803–809. doi: 10.1056/NEJM197910113011502. [DOI] [PubMed] [Google Scholar]
  6. Roubinian J. R., Papoian R., Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest. 1977 Jun;59(6):1066–1070. doi: 10.1172/JCI108729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Roubinian J. R., Talal N., Greenspan J. S., Goodman J. R., Siiteri P. K. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest. 1979 May;63(5):902–911. doi: 10.1172/JCI109390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Roubinian J. R., Talal N., Greenspan J. S., Goodman J. R., Siiteri P. K. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med. 1978 Jun 1;147(6):1568–1583. doi: 10.1084/jem.147.6.1568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Verheul H. A., Stimson W. H., den Hollander F. C., Schuurs A. H. The effects of nandrolone, testosterone and their decanoate esters on murine lupus. Clin Exp Immunol. 1981 Apr;44(1):11–17. [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES